Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) has today, June 28th 2021, received information about the granting of Mexican patent application concerning the company's front-line product Temodex / SI-053.
Patent approval provides protection for the technology and the product in Mexico until at least 2036.
"This is a very important milestone in the development of SI-053 as Mexico is a fast growing market where we plan to expand the global commercialization of the product," comments Igor Lokot, CEO of DBP. – “We also have other applications pending for other important markets."
More about Temodex/SI-053: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared under the name SI-053 to pass through all the tests and trials required for registration within the EU and globally. Video presentation: https://youtu.be/iweOQPq316o 

This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 29-06-2021 08:40 CET.

____________________________________________________________________
Full Company Name:   Double Bond Pharmaceutical International AB (publ)
Corporate identity:       556991-6082
Stock short name:       DBP B
Share ISIN code:          SE0007185525 

For more info, contact
Igor Lokot, CEO
Homepage: http://www.doublebp.com/
E-mail: info@doublebp.com

Follow us on LinkedIn and Twitter!
_______________________________________________________________________________

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.